Author
Listed:
- Anthony Stein
(City of Hope)
- Janet L. Franklin
(Global Patient Safety, Amgen Inc)
- Victoria M. Chia
(Global Patient Safety, Amgen Inc)
- Deborah Arrindell
(Global Patient Safety, Amgen Inc)
- William Kormany
(Global Patient Safety, Amgen Inc)
- Jacqueline Wright
(Global Patient Safety, Amgen Inc)
- Mandy Parson
(Global Patient Safety, Amgen Inc)
- Hamid R. Amouzadeh
(Global Patient Safety, Amgen Inc)
- Jessica Choudhry
(Global Patient Safety, Amgen Inc)
- Guiandre Joseph
(Global Patient Safety, Amgen Inc)
Abstract
Blinatumomab is the first-and-only Food and Drug Administration (FDA)-approved cluster of differentiation (CD) 19-directed CD3 bispecific T-cell engager (BiTE®) immunotherapy. It is currently FDA approved for the treatment of adults and children with Philadelphia chromosome-positive (Ph+) and Philadelphia chromosome-negative (Ph−) relapsed/refractory (R/R) B-cell precursor acute lymphoblastic leukemia (ALL) and B-cell precursor ALL with minimal residual disease. Similarly, initial marketing authorization for blinatumomab in the European Union was granted for the treatment of adults with Ph− R/R B-cell precursor ALL. The benefits of treating R/R B-cell precursor ALL patients with blinatumomab include increased overall survival, more favorable hematologic remission and molecular response rates, and a lower incidence rate of selected adverse events when compared with standard-of-care chemotherapy. The key risks associated with blinatumomab treatment include cytokine release syndrome, neurotoxicity, and medication errors. Here, we review the benefits and risks of blinatumomab treatment and describe how these risks can be mitigated.
Suggested Citation
Anthony Stein & Janet L. Franklin & Victoria M. Chia & Deborah Arrindell & William Kormany & Jacqueline Wright & Mandy Parson & Hamid R. Amouzadeh & Jessica Choudhry & Guiandre Joseph, 2019.
"Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia,"
Drug Safety, Springer, vol. 42(5), pages 587-601, May.
Handle:
RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0760-1
DOI: 10.1007/s40264-018-0760-1
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:42:y:2019:i:5:d:10.1007_s40264-018-0760-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.